Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 18/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5176461 | 0.91 | PGR (0.43) | PGRTRPV4ARCYP2C9CYP2D6 | |
| SCHEMBL4901561 | 0.87 | PGR (0.45) | PGRTRPV4ARCYP2C19 | |
| SCHEMBL4901568 | 0.87 | PGR (0.45) | PGRTRPV4ARCYP2C19 | |
| SCHEMBL4894270 | 0.84 | PGR (0.49) | PGRARCYP2C19 | |
| SCHEMBL4894275 | 0.84 | PGR (0.49) | PGRARCYP2C19 | |
| SCHEMBL4901224 | 0.84 | MAOA (0.41) | PGRAR | |
| SCHEMBL2677378 | 0.82 | TRPV4 (0.52) | PGRTRPV4ARCYP2C19 | |
| SCHEMBL4904296 | 0.80 | PGR (0.50) | PGRCYP2C19 | |
| SCHEMBL4893922 | 0.79 | PGR (0.53) | PGRCYP2C19 | |
| SCHEMBL3061114 | 0.77 | PGR (0.44) | PGRTRPV4ARCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | US | claimed |
| EP-1747193-A1 | BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY | Pfizer Products Incorporated (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2006024931-A2 | THERAPEUTIC COMBINATIONS COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND A SELECTIVE ANDROGEN RECEPTOR MODULATOR | PFIZER PRODUCTS INC. (US) | 2006-03-09 | — | — | WO | claimed |
| WO-2005108351-A1 | BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY | PFIZER PRODUCTS INC. (US) | 2005-11-17 | — | — | WO | claimed |
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | US | disclosed |
| EP-1747193-A1 | BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY | Pfizer Products Incorporated (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2006024931-A2 | THERAPEUTIC COMBINATIONS COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND A SELECTIVE ANDROGEN RECEPTOR MODULATOR | PFIZER PRODUCTS INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005108351-A1 | BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY | PFIZER PRODUCTS INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | TNNC1, TNNI3, TNNT2 | PGR 1921/4885TRPV4 2146/4885AR 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.